title: Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri.
abstract: BACKGROUND
  In pseudotumor cerebri (PTC), elevated intracranial pressure (ICP) results in papilledema and, rarely, choroidal neovascularization (CNV). Pseudotumor cerebri-induced CNV often regresses following medical or surgical ICP reduction, but additional treatments, such as photocoagulation, photodynamic therapy, peri-ocular steroid injections and/or subretinal surgery, may be necessary. Anti-angiogenic intravitreal injections have been shown to cause regression of both CNV and optic nerve edema.
  
  
  METHODS
  We describe a patient with PTC and CNV whose CNV regressed and vision normalized after a single intravitreal injection of bevacizumab (Avastin; Genentech, San Francisco, CA).
authors.affiliation: Department of Ophthalmology, West Virginia University, 1 Stadium Drive, Morgantown, WV 26506, US. sjamerson@hsc.wvu.edu
authors.forename: Scott C
authors.initials: SC
authors.lastname: Jamerson
authors.forename: Guruswami
authors.initials: G
authors.lastname: Arunagiri
authors.forename: Brian D
authors.initials: BD
authors.lastname: Ellis
authors.forename: Monique J
authors.initials: MJ
authors.lastname: Leys
mesh_terms: D000086:Acetazolamide / Q000008:administration & dosage; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D004232:Diuretics / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010211:Papilledema / Q000209:etiology; D011559:Pseudotumor Cerebri / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011681:Pupil Disorders / Q000209:etiology; D016896:Treatment Outcome; D014792:Visual Acuity; D014794:Visual Fields
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004232:Diuretics; D000068258:Bevacizumab; D000086:Acetazolamide